Kwon Ok-Seon, Lee Haeseung, Kim Yun-Jeong, Cha Hyuk-Jin, Song Na-Young, Lee Mi-Ok
Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.
Intellectual Information Team, Future Medicine Division, Korea Institute of Oriental Medicine, Daejeon 34054, Korea.
Cancers (Basel). 2020 Apr 8;12(4):909. doi: 10.3390/cancers12040909.
The role of Situin 1 (SIRT1) in tumorigenesis is still controversial due to its wide range of substrates, including both oncoproteins and tumor suppressors. A recent study has demonstrated that SIRT1 interferes in the Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven activation of the Raf-mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK)-ERK pathway, thereby inhibiting tumorigenesis. However, the molecular mechanism of SIRT1 as a tumor suppressor in RAS-driven tumorigenesis has been less clearly determined. This study presents evidence that the ectopic expression of SIRT1 attenuates RAS- or MEK-driven ERK activation and reduces cellular proliferation and transformation in vitro. The attenuation of ERK activation by SIRT1 results from prompt dephosphorylation of ERK, while MEK activity remains unchanged. We identified that MKP1, a dual specific phosphatase for MAPK, was deacetylated by SIRT1. Deacetylation of MKP1 by direct interaction with SIRT1 increased the binding affinity to ERK which in turn facilitated inactivation of ERK. Taken together, these results suggest that SIRT1 would act as a tumor suppressor by modulating RAS-driven ERK activity through MKP1 deacetylation.
由于沉默信息调节因子1(SIRT1)的底物范围广泛,包括癌蛋白和肿瘤抑制因子,其在肿瘤发生中的作用仍存在争议。最近一项研究表明,SIRT1干扰 Kirsten 大鼠肉瘤病毒癌基因同源物(KRAS)驱动的 Raf-丝裂原活化蛋白激酶(MAPK)/细胞外信号调节激酶(ERK)激酶(MEK)-ERK 通路的激活,从而抑制肿瘤发生。然而,SIRT1作为RAS驱动的肿瘤发生中的肿瘤抑制因子的分子机制尚未明确确定。本研究提供的证据表明,SIRT1的异位表达减弱了RAS或MEK驱动的ERK激活,并在体外降低了细胞增殖和转化。SIRT1对ERK激活的减弱是由于ERK的快速去磷酸化,而MEK活性保持不变。我们发现,MAPK的双特异性磷酸酶MKP1被SIRT1去乙酰化。MKP1通过与SIRT1直接相互作用去乙酰化,增加了对ERK的结合亲和力,进而促进ERK的失活。综上所述,这些结果表明,SIRT1通过MKP1去乙酰化调节RAS驱动的ERK活性,从而发挥肿瘤抑制因子的作用。